Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3,4-dihydro-8-(2-hydroxy-3--isopropylaminopropoxy)-3-nitroxy-2h-1-benzopyran
2. K 351
3. K-351
1. Nipradolol
2. 81486-22-8
3. Hypadil
4. Hypadil (tn)
5. K 351
6. Fvm336i71y
7. 8-(2-hydroxy-3-(isopropylamino)propoxy)chroman-3-yl Nitrate
8. 8-(2-hydroxy-3-(isopropylamino)propoxy)-3-chromanol, 3-nitrate
9. [8-[2-hydroxy-3-(propan-2-ylamino)propoxy]-3,4-dihydro-2h-chromen-3-yl] Nitrate
10. Hypadil; K 351; Kt 210; Nipradilo
11. Nipradilolum [latin]
12. Nipradilolum
13. Nipradilol [inn:jan]
14. Ccris 2515
15. Brn 3566879
16. Unii-fvm336i71y
17. Nipranol
18. 8-(2-hydroxy-3-(isopropylamino)propoxy)-3-chromanyl Nitrat
19. Nipradilol [mi]
20. 8-(2-hydroxy-3-(isopropylamino)propoxy)-3-chromanol 3-nitrate
21. Nipradilol (jan/inn)
22. Nipradilol [inn]
23. Nipradilol [jan]
24. Nipradilol [inci]
25. K-351
26. 3,4-dihydro-8-(2-hydroxy-3-isopropylamino)propoxy-3-nitroxy-2h-1-benzopyran
27. Nipradilol [mart.]
28. 3,4-dihydro-8-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2h-1-benzopyran-3-ol 3-nitrate
29. 3,4-dihydro-8-(2-hydroxy-3-(isopropylamino)propoxy)-2h-1-benzopyran-3-ol 3-nitrate
30. Nipradolol [who-dd]
31. Schembl48884
32. Chembl155622
33. Chebi:31682
34. Dtxsid30868615
35. Bcp04466
36. Kt-210
37. Akos016014067
38. 2h-1-benzopyran-3-ol, 3,4-dihydro-8-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, 3-nitrate
39. Ft-0630894
40. D01691
41. L013397
42. Q15634005
43. 3,4-dihydro-8-(2-hydroxy-3-isopropylaminopropoxy)-3-nitroxy-2h-1-benzopyran
44. 3-nitroxy-8-[(2-hydroxy-3-isopropylamino)propoxy]-3,4(2h)-dihydro-1-benzopyran
45. 8-[2-hydroxy-3-(isopropylamino)propoxy]-3,4-dihydro-2h-chromen-3-yl Nitrate #
46. 8-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}-3,4-dihydro-2h-1-benzopyran-3-yl Nitrate
| Molecular Weight | 326.34 g/mol |
|---|---|
| Molecular Formula | C15H22N2O6 |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 7 |
| Exact Mass | 326.14778643 g/mol |
| Monoisotopic Mass | 326.14778643 g/mol |
| Topological Polar Surface Area | 106 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 376 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Adrenergic alpha-Antagonists
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)
Adrenergic beta-Antagonists
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)
ABOUT THIS PAGE
A Nipradilol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nipradilol, including repackagers and relabelers. The FDA regulates Nipradilol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nipradilol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nipradilol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nipradilol supplier is an individual or a company that provides Nipradilol active pharmaceutical ingredient (API) or Nipradilol finished formulations upon request. The Nipradilol suppliers may include Nipradilol API manufacturers, exporters, distributors and traders.
click here to find a list of Nipradilol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Nipradilol Drug Master File in Japan (Nipradilol JDMF) empowers Nipradilol API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Nipradilol JDMF during the approval evaluation for pharmaceutical products. At the time of Nipradilol JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Nipradilol suppliers with JDMF on PharmaCompass.
Nipradilol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nipradilol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nipradilol GMP manufacturer or Nipradilol GMP API supplier for your needs.
A Nipradilol CoA (Certificate of Analysis) is a formal document that attests to Nipradilol's compliance with Nipradilol specifications and serves as a tool for batch-level quality control.
Nipradilol CoA mostly includes findings from lab analyses of a specific batch. For each Nipradilol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nipradilol may be tested according to a variety of international standards, such as European Pharmacopoeia (Nipradilol EP), Nipradilol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nipradilol USP).
LOOKING FOR A SUPPLIER?
